secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neumora Therapeutics, Inc. (NMRA)
CIK:        0001885522
Form:       8-K/A
Filed at:   2025-02-21T23:59:59+00:00
Accession:  0001193125-25-031974
Event type: leadership
Sentiment:  neutral
Materiality: 0.75
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Neumora Therapeutics appoints Paul Berns as Chairman & CEO, Gosebruch exits
---------------------------------------------------------------------------

- Henry Gosebruch separates as CEO; receives 12-month base salary, 2025 target bonus, 18-month COBRA, 2024 bonus, and 12-month option exercise period.
- Paul L. Berns appointed Chairman & CEO with $700,000 base salary and 60% annual bonus target, effective Feb 14, 2025.
- Berns receives option to purchase 2,000,000 shares vesting over 4 years (25% after 1 year, monthly thereafter).
- Berns severance: 12 months salary + bonus (non-CIC); 24 months salary + 2x bonus + equity acceleration (CIC-related).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1885522/000119312525031974/0001193125-25-031974-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1885522/000119312525031974/d862857d8ka.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-031974

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer